0000000000001679

AUTHOR

Emanuele S.g. D'amore

showing 4 related works from this author

Peripheral neuroblastic tumors with genotype-phenotype discordance: A report from the Children's Oncology Group and the International Neuroblastoma P…

2012

Background Of 4,706 peripheral neuroblastic tumors (pNTs) registered on the Children’s Cancer Group and Children’s Oncology Group Neuroblastoma Study between 1989 and 2010, 51 cases (1.1%) had genotype-phenotype discordance characterized by MYCN amplification (indicating poor prognosis) and Favorable Histology (indicating better prognosis).

OncologyPathologymedicine.medical_specialtybusiness.industryCancerHematologymedicine.diseaseNeuroblastic TumorN-Myc Proto-Oncogene ProteinGenotype phenotypePeripheralOncologyNeuroblastomaInternal medicinePediatrics Perinatology and Child HealthMycn amplificationMedicineImmunohistochemistrybusinessneoplasmsPediatric Blood & Cancer
researchProduct

Transcriptional analysis distinguishes breast implant-associated anaplastic large cell lymphoma from other peripheral T-cell lymphomas

2019

Breast implant-associated anaplastic large cell lymphoma is a new provisional entity in the revised World Health Organization classification of lymphoid malignancies, the pathogenesis and cell of origin of which are still unknown. We performed gene expression profiling of microdissected breast implant-associated anaplastic large cell lymphoma samples and compared their transcriptional profiles with those previously obtained from normal T-cells and other peripheral T-cell lymphomas and validated expression of selected markers by immunohistochemistry. Our results indicate that most breast implant-associated anaplastic large cell lymphomas exhibit an activated CD4+ memory T-cell phenotype, whi…

Adult0301 basic medicinePathologymedicine.medical_specialtyBreast ImplantsCell of originT cell2734BiologyPathology and Forensic Medicine03 medical and health sciences0302 clinical medicineImmunophenotypingMyeloid Cell Differentiationhemic and lymphatic diseasesmedicineHumansRPS10Anaplastic large-cell lymphomaBreast implant-associated anaplastic large cell lymphomabreast implant-associatedanaplastic large cell lymphoma gene expression profiling RPS10Large cellLymphoma T-Cell Peripheralmedicine.diseaseimmunophenotypeLymphomaGene expression profiling030104 developmental biologymedicine.anatomical_structureTranscriptional analysi030220 oncology & carcinogenesisgene expressionLymphoma Large-Cell Anaplasticgene expression; C-Met; lymphoproliferative disorderFemaleC-Metlymphoproliferative disorderTranscriptome
researchProduct

Prognostic value of International Neuroblastoma Pathology Classification in localized resectable peripheral neuroblastic tumors: a histopathologic st…

2006

Purpose To assess the prognostic value of clinical, biologic, and morphologic data in peripheral neuroblastic tumors, International Neuroblastoma Staging System (INSS) stages 2A and 2B MYCN nonamplified, a multinational protocol entitled Localized Neuroblastoma European Study Group trial 94.01, with a trial of surgery as the only treatment, was initiated in 1995. We present the prognostic value of the revised International Neuroblastoma Pathology Classification (INPC) applied to the patients included in this protocol until its closure in 1999. Materials and Methods A total of 120 neuroblastic tumors from trial patients were reviewed by the European International Society of Pediatric Oncolog…

Cancer Researchmedicine.medical_specialtyPathologyDisease-Free SurvivalNeuroblastomaPredictive Value of TestsNeuroblastomamedicineHumansSurvival analysisGanglioneuroblastomaL-Lactate Dehydrogenasebusiness.industryGanglioneuroblastomaAnatomical pathologymedicine.diseasePrognosisNeuroblastic TumorSurvival AnalysisClinical trialEuropeTreatment OutcomeOncologyPredictive value of testsHistopathologybusinessJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

Prognostic Factors in Childhood Anaplastic Large Cell Lymphoma: Long Term Results of the International ALCL99 Trial

2020

With the aim of describing the long-term follow-up and to define the prognostic role of the clinical/pathological/molecular characteristics at diagnosis for childhood, adolescent and young adults affected by anaplastic large cell lymphoma (ALCL), we analyzed 420 patients aged up to 22 years homogeneously treated within the international ALCL99 trial. The 10-year progression free survival (PFS) was 70% and overall survival was 90%, rare late relapses occurred but no secondary malignancies were reported. Among clinical/pathological characteristics, only patients presenting a small cell/lymphohistiocytic (SC/LH) pattern were independently associated with risk of failure (hazard ratio = 2.49). …

MDD0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyMultivariate analysisIMPACTBONE-MARROWFEATURESCHILDRENlong-term follow-uplcsh:RC254-282ArticleDISEASECLASSIFICATIONChildhood Anaplastic Large Cell Lymphoma03 medical and health sciences0302 clinical medicineInternal medicineADOLESCENTSmedicineVINBLASTINEProgression-free survivalYoung adultPathologicalAnaplastic large-cell lymphomachildhoodScience & Technologybusiness.industryHazard ratioCHEMOTHERAPYlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseALCLALCL; MDD; childhood; long-term follow-up030104 developmental biologyOncology030220 oncology & carcinogenesisMinimal Disseminated DiseaseNON-HODGKIN-LYMPHOMAbusinessLife Sciences & BiomedicineCancers
researchProduct